Shanghai Pharmaceuticals' bid for Cardinal Malaysia subject to Mofcom’s approval
The takeover of Cardinal Malaysia by Shanghai Pharmaceuticals will require antitrust approval from China’s Ministry of Commerce. The Shanghai-based, state-controlled pharmaceutical company is expected to pay about $557 million to buy all...To view the full article, register now.
Already a subscriber? Click here to view full article